KR890015738A - 이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물 - Google Patents

이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물 Download PDF

Info

Publication number
KR890015738A
KR890015738A KR1019890004619A KR890004619A KR890015738A KR 890015738 A KR890015738 A KR 890015738A KR 1019890004619 A KR1019890004619 A KR 1019890004619A KR 890004619 A KR890004619 A KR 890004619A KR 890015738 A KR890015738 A KR 890015738A
Authority
KR
South Korea
Prior art keywords
acid
amino
phosphonic acid
acid derivative
pharmaceutical composition
Prior art date
Application number
KR1019890004619A
Other languages
English (en)
Other versions
KR0135420B1 (ko
Inventor
펠 쨩-삐에르
그로매닐 쟝-끌로드
아브라모비씨 베르나르
Original Assignee
원본미기재
소시에떼 아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9365083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890015738(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 소시에떼 아노님 사노피 filed Critical 원본미기재
Publication of KR890015738A publication Critical patent/KR890015738A/ko
Application granted granted Critical
Publication of KR0135420B1 publication Critical patent/KR0135420B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 이포스폰산 유도체에 대하여 나트륨 라우릴 술페이드 1.5내지 6중량%를 함유함을 특징으로 하는, 하기 일반식(I)의 이포스폰산 유도체 또는 그의 약학적으로 허용 가능한 염 중의 하나를 기재로 하는 경구 투여용 약학적 조성물.
    (식중, R1은 수소원자, 할로겐원자, 히드록실, 아미노 또는 디알킬(C1~C4)아미노를 나타내고, R2는 할로겐원자, 비치환 또는 염소원자에 의해 치환된 1내지 5개의 탄소원자를 함유하는 선형알킬, 히드록실, 아미노 또는 디알킬(C1~C4)아미노를 나타내거나, 또는 페녹시, 페닐, 티올, 페닐티오, 클로로페닐티오, 피리딜 또는 티오모르폴린-4-일을 나타낸다).
  2. 제 1 항에 있어서, 이포스폰산유도체가 에티드론산, 피리드론산, 클로로론산, 파미드론산, 4-클로로페닐티오메틸렌디 포스폰산, 4-아미노-1-히드록시부틸리덴디포스폰산, 6-아미노-1-하드록시헥실리덴디포스폰산, 페녹시메틸렌디포스폰산, 티오모르폴리노메틸렌디포스폰산 또는 그들의 약학적으로 허용가능한 염중의 하나로 부터 선택됨을 특징으로 하는 약학적 조성물.
  3. 제 1 항에 있어서, 이포스폰산유도체가 4-클로로페닐티오메틸렌디포스폰산 또는 그의 이나트륨염 임을 특징으로 하는 약학적 조성물.
  4. 제 1 항 내지 3항중 어느 한 항에 있어서, 100내지 500mg의 4-클로로페닐티오메틸렌디포스폰산 또는 동량의 그의 이나트륨염, 및 1.7내지 4중량%의 나트륨라우릴레이트를 함유함을 특징으로 하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890004619A 1988-04-07 1989-04-07 이포스폰산 유도체를 기제로 하는 경구 투여용 약학적 조성물 KR0135420B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8804628A FR2629716B1 (fr) 1988-04-07 1988-04-07 Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FR8804628 1988-04-07
FR88/04628 1988-04-07

Publications (2)

Publication Number Publication Date
KR890015738A true KR890015738A (ko) 1989-11-25
KR0135420B1 KR0135420B1 (ko) 1998-04-23

Family

ID=9365083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890004619A KR0135420B1 (ko) 1988-04-07 1989-04-07 이포스폰산 유도체를 기제로 하는 경구 투여용 약학적 조성물

Country Status (15)

Country Link
US (1) US4980171A (ko)
EP (1) EP0336851B1 (ko)
JP (1) JP2602947B2 (ko)
KR (1) KR0135420B1 (ko)
AU (1) AU618796B2 (ko)
CA (1) CA1327009C (ko)
DE (1) DE68900994D1 (ko)
DK (1) DK166989A (ko)
FR (1) FR2629716B1 (ko)
IE (1) IE60923B1 (ko)
IL (1) IL89868A (ko)
NZ (1) NZ228617A (ko)
OA (1) OA09415A (ko)
PH (1) PH26647A (ko)
ZA (1) ZA892557B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
ES2065313T5 (es) * 1993-05-15 2004-01-01 Roche Diagnostics Gmbh Tableta con biodisponibilidad mejorada que contiene acido diclorometilendifosfonico como sustancia activa.
ATE165636T1 (de) * 1993-10-26 1998-05-15 Akzo Nobel Nv Aminoalkan-diphosphonsäuren zum bleichen von zellstoff
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AU4782600A (en) * 1999-06-02 2000-12-28 Procter & Gamble Company, The Oral preparations of etidronate disodium
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
MXPA03006565A (es) * 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
SI1596870T2 (sl) 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
MXPA06003063A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato.
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
WO2007048263A2 (de) * 2005-10-27 2007-05-03 Nexilis Ag Implantat und verfahren zu dessen herstellung
WO2007048264A1 (de) * 2005-10-27 2007-05-03 Thommen Medical Ag Dentalimplantat und verfahren zu dessen herstellung
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
FR2954320B1 (fr) * 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
FR2975300B1 (fr) * 2011-05-19 2013-06-07 Thierry Breul Composition pharmaceutique a biodisponibilite amelioree
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
WO2019032876A1 (en) 2017-08-09 2019-02-14 Sharkninja Operating Llc COOKING DEVICE AND COMPONENTS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2534390C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1,3-Di-aminoalkan-1,1-diphosphonsäuren
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
GB2135879B (en) * 1983-03-07 1986-05-21 Ciba Geigy Ag Pharmaceutical preparations with uniform elution properties
US4902679A (en) * 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates

Also Published As

Publication number Publication date
IL89868A (en) 1993-08-18
IE891103L (en) 1989-10-07
AU618796B2 (en) 1992-01-09
IE60923B1 (en) 1994-09-07
DK166989A (da) 1989-10-08
NZ228617A (en) 1992-02-25
CA1327009C (en) 1994-02-15
FR2629716B1 (fr) 1991-07-19
US4980171A (en) 1990-12-25
EP0336851A1 (fr) 1989-10-11
EP0336851B1 (fr) 1992-03-18
FR2629716A1 (fr) 1989-10-13
KR0135420B1 (ko) 1998-04-23
PH26647A (en) 1992-09-04
OA09415A (fr) 1992-10-15
JP2602947B2 (ja) 1997-04-23
ZA892557B (en) 1989-12-27
AU3258889A (en) 1989-10-12
DK166989D0 (da) 1989-04-06
DE68900994D1 (de) 1992-04-23
IL89868A0 (en) 1989-12-15
JPH026409A (ja) 1990-01-10

Similar Documents

Publication Publication Date Title
KR890015738A (ko) 이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물
CA2120538A1 (en) Use of Bisphosphonic Acid Derivatives for Promoting Bone Repair and Corresponding Drugs
OA07934A (fr) Nouveaux dérivés de la xanthine, leurs procédés de préparation et les compositions pharmaceutiques les renfermant.
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
GR3029603T3 (en) Cytotoxic stilbene derivatives and pharmaceutical composition containing them.
BR9807814A (pt) Composto, composição farmacêutica, uso de um composto, e, processos de tratamento e para preparação de um composto
KR910700073A (ko) 마크로사이클릭 아미노포스폰산 착화합물, 그의 제조방법, 이를 포함하는 배합물 및 용도
FR2478636B1 (ko)
KR840007596A (ko) 유기인 유도체의염의 제조방법
KR950702580A (ko) 니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes)
KR900013965A (ko) 상피소체 호르몬 합성 및 분비억제
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
CY1104974T1 (el) Χρηση παραγωγου του διφωσφονικου οξεος για τηn παρασκευη ενος φαρμακου που προοριζεται για τη θεραπεια της χωλοτητας
KR880009654A (ko) 아세트알데히드의 독성을 감소시키는 조성물 및 방법
SE8205867D0 (sv) Noveaux derives de l'acide 4-phenyl 4-oxo 2-butenoique, leurs sels, leur preparation leur application comme medicaments et les compositions les renfermant
PT87734A (pt) Procede de preparation de nouveaux tripeptides a structure polycyclique azotee et de compositions pharmaceutiques les contenant
KR890009922A (ko) 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온
ATE210987T1 (de) Minderung der toxischen effekte des carboplatins durch verwendung von dithioethern
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
KR880013562A (ko) 7-티아프로스타글란딘e₁ 또는 그의 유도체를 함유하는 당뇨병치료 조성물
KR910000738A (ko) 미토마이신 포스페이트 유도체류
KR900003195A (ko) 2'-메틸리덴피리미딘 뉴클레오시드 화합물, 그의 용도 및 제조방법
EE9800134A (et) Farmatseutiline kompositsioon intravenoosseks manustamiseks
KR910004192A (ko) 프로페니토인의 치료적 유효량을 함유하는 발작증 치료용 제약 조성물
KR950702566A (ko) 사슬형 아미딘기를 포함하는 디포스폰산 유도체, 그것의 제조방법 및 그것을 포함하는 의약 조성물(novel acyclic amidine-group-containing diphosphonic acid derivatives, process for producing them and medicaments containing these compounds)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030109

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee